SCHEMBL3548799

SCHEMBL3548799

N#Cc1c(Cl)nc(Sc2ccccc2)c(C#N)c1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
MAPT P10636 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
ADORA1 P30542 1/20 0.48
ALDH1A1 P00352 6/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ALOX15 P16050 2/20 0.47
L3MBTL1 Q9Y468 5/20 0.46
CYP1A2 P05177 4/20 0.45
CYP2C9 P11712 4/20 0.45
CYP2C19 P33261 4/20 0.45
TDP1 Q9NUW8 2/20 0.45
HTT P42858 3/20 0.43
HPGD P15428 2/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13849107 0.87 KDM4E (0.52) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL245593 0.87 ADORA1 (0.64) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL11924383 0.84 KDM4E (0.44) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL161948 0.84 L3MBTL1 (0.60) KDM4ERXFP1ADORA1ALDH1A1MEN1
SCHEMBL3598171 0.83 ADORA1 (0.50) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL28185531 0.82 KDM4E (0.73) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL3544024 0.80 L3MBTL1 (0.45) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL251890 0.78 ALDH1A1 (0.62) KDM4EMAPTADORA1ALDH1A1MEN1
SCHEMBL244863 0.78 ADORA1 (0.61) KDM4EMAPTNPSR1RXFP1ADORA1
SCHEMBL13938147 0.78 ADORA1 (0.62) KDM4EMAPTNPSR1RXFP1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-7825255-B2 Adenosine receptor selective modulators BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-02 US disclosed
US-7825255-B2 Adenosine receptor selective modulators BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-02 US disclosed
US-7825255-B2 Adenosine receptor selective modulators BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-02 US disclosed
EP-1373265-B1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER HEALTHCARE AG (DE) 2009-05-06 EP disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
EP-1368319-B1 SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER HEALTHCARE AG (DE) 2006-12-06 EP disclosed
US-20060154969-A1 Adenosine receptor selective modulators BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-07-13 US disclosed
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2004-08-19 US disclosed
EP-1373265-A1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS Bayer HealthCare AG (DE) 2004-01-02 EP disclosed
EP-1368319-A1 SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS Bayer Aktiengesellschaft (DE) 2003-12-10 EP disclosed
WO-2002070520-A1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER AKTIENGESELLSCHAFT (DE) 2002-09-12 WO disclosed
WO-2002070485-A1 SUBSTITUTED 2-THIO-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER AKTIENGESELLSCHAFT (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands ADORA2A, ADORA3, ADORA1 KDM4E 2957/4885MAPT 4364/4885NPSR1 81/4885
US-20060154969-A1 Adenosine receptor selective modulators ADORA2A, ADORA1, ADORA3 KDM4E 3354/4885MAPT 4779/4885NPSR1 63/4885
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands ADORA3, ADORA1, ADORA2A KDM4E 1607/4885MAPT 4350/4885NPSR1 264/4885
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands ADORA3, ADORA1, ADORA2A KDM4E 1609/4885MAPT 4461/4885NPSR1 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.